These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 29656114

  • 1. Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.
    Weston VJ, Wei W, Stankovic T, Kearns P.
    Exp Hematol; 2018 Jul; 63():52-63.e5. PubMed ID: 29656114
    [Abstract] [Full Text] [Related]

  • 2. Upstream and downstream mechanisms for the promoting effects of IGF-1 on differentiation of spermatogonia to primary spermatocytes.
    Shen G, Wu R, Liu B, Dong W, Tu Z, Yang J, Xu Z, Pan T.
    Life Sci; 2014 Apr 17; 101(1-2):49-55. PubMed ID: 24582811
    [Abstract] [Full Text] [Related]

  • 3. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
    Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, Spreafico A, Kachaeva MI, Selby HM, Tentler JJ, Eckhardt SG, Leong S.
    Clin Cancer Res; 2013 Nov 15; 19(22):6219-29. PubMed ID: 24045180
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
    Hu Y, Dragowska WH, Wallis A, Duronio V, Mayer L.
    Breast Cancer Res Treat; 2001 Nov 15; 70(1):11-20. PubMed ID: 11767000
    [Abstract] [Full Text] [Related]

  • 5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 15; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.
    Kawashima I, Mitsumori T, Nozaki Y, Yamamoto T, Shobu-Sueki Y, Nakajima K, Kirito K.
    Exp Hematol; 2015 Jul 15; 43(7):524-33.e1. PubMed ID: 25846811
    [Abstract] [Full Text] [Related]

  • 9. IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase.
    Kooijman R, Coppens A, Hooghe-Peters E.
    Cell Signal; 2003 Dec 15; 15(12):1091-8. PubMed ID: 14575864
    [Abstract] [Full Text] [Related]

  • 10. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
    Jang K, Kim M, Seo HS, Shin I.
    Oncol Rep; 2010 Sep 15; 24(3):787-93. PubMed ID: 20664988
    [Abstract] [Full Text] [Related]

  • 11. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC, Sandoval JA, Klein PJ, Woodruff HA, Grosfeld JL, Hickey RJ, Malkas LH, Schmidt CM.
    J Pediatr Surg; 2006 Jan 15; 41(1):252-9. PubMed ID: 16410143
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V, Borgo C, Cesaro L, Pinna LA, Donella-Deana A.
    Oncotarget; 2016 Apr 05; 7(14):18204-18. PubMed ID: 26919095
    [Abstract] [Full Text] [Related]

  • 13. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
    Yip-Schneider MT, Schmidt CM.
    Pancreas; 2003 Nov 05; 27(4):337-44. PubMed ID: 14576498
    [Abstract] [Full Text] [Related]

  • 14. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
    Fukazawa H, Noguchi K, Murakami Y, Uehara Y.
    Mol Cancer Ther; 2002 Mar 05; 1(5):303-9. PubMed ID: 12489846
    [Abstract] [Full Text] [Related]

  • 15. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
    Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C, Van Waes C.
    Clin Cancer Res; 2001 Feb 05; 7(2):435-42. PubMed ID: 11234901
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
    Xiao RZ, He CM, Xiong MJ, Ruan XX, Wang LL, Chen Y, Lin DJ.
    Oncol Rep; 2013 May 05; 29(5):1895-901. PubMed ID: 23467984
    [Abstract] [Full Text] [Related]

  • 17. Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor.
    Lecat S, Belemnaba L, Galzi JL, Bucher B.
    Cell Signal; 2015 Jul 05; 27(7):1297-304. PubMed ID: 25817573
    [Abstract] [Full Text] [Related]

  • 18. Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells.
    Gingras S, Côté S, Simard J.
    Mol Endocrinol; 2000 Feb 05; 14(2):229-40. PubMed ID: 10674396
    [Abstract] [Full Text] [Related]

  • 19. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
    Miyata N, Azuma T, Hozawa S, Higuchi H, Yokoyama A, Kabashima A, Igarashi T, Saeki K, Hibi T.
    Pancreas; 2012 Jul 05; 41(5):745-52. PubMed ID: 22441145
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO, Kalmadi S, Eastman A.
    Breast Cancer Res Treat; 2005 Sep 05; 93(2):177-88. PubMed ID: 16187238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.